Autopsy report · NCT06524804
A Phase Ib/II Study of BY101298 , an Oral DNA-PK Inhibitor, Combined with Radiotherapy in Patients with Malignant Solid Tumors
Cause of deathFunding or business
“The sponsor adjusts the clinical development strategy.”
Life of this trial
- Registered 2 months after it had already started.
- Ran for about 5 months before it stopped.
- 60 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 1, Phase 2
- Sponsor
- Chengdu Baiyu Pharmaceutical Co., Ltd.
- Sponsor type
- Industry
- Conditions
- Solid Tumor, Adult
- Interventions
- BY101298 Capsules; palliative radiotherapy; BY101298 Capsules; curative radiotherapy
- Participants
- 60
- Sites
- 1
- Countries
- China
Trials that died the same way
- A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Solid Tumors
“Sponsor's clinical development strategy adjustment” - A Clinical Trial of YH1177 in Patients With Otitis Media and Otorrhea
“Sponsor's decision for the Drug Development.” - A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer
“Sponsor Decision; strategic - based on changing treatment landscape” - A Study of GFH312 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication (IC)
“The study was terminated by sponsor for reasons of adjusted clinical development strategy.” - Study to Investigate the Safety of LT5001 Drug Product for Uremic Pruritus in Hemodialysis Patients
“Change in the clinical development plan”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.